Nervous system
Memantine (NMDA receptor antagonist)
An NMDA receptor antagonist that damps excessive glutamate stimulation, which may contribute to neuronal injury; used in moderate to severe Alzheimer disease, alone or with a cholinesterase inhibitor.
Mécanisme d’action
- In Alzheimer disease, chronic low-level glutamate overstimulation of NMDA receptors lets in too much calcium (excitotoxicity).
- Memantine blocks the open NMDA channel with low affinity and fast kinetics.
- Pathological, tonic activation is reduced while the brief, strong activation needed for learning is spared.
Cibles moléculaires
- NMDA glutamate receptor channel: Uncompetitive (open-channel) blocker
Médicaments : Memantine (NMDA receptor antagonist)
- Memantine (By mouth; cleared by the kidney.)
Indications thérapeutiques
- Moderate to severe Alzheimer disease, alone or added to donepezil
Maladies traitées
Effets indésirables
- Dizziness and headache
- Confusion and agitation
- Constipation
Contre-indications selon le terrain
- Kidney impairment (Avec précaution): It is excreted by the kidney and accumulates.
- Epilepsy (Avec précaution): It may lower the seizure threshold.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 8, Drugs for Neurodegenerative Diseases, NMDA receptor antagonist
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 60, Special Aspects of Geriatric Pharmacology, Alzheimer disease
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.